PerkinElmer, Inc.

686 articles with PerkinElmer, Inc.

• PerkinElmer to Present at Baird's 2020 Virtual Global Healthcare Conference

  8/19/2020

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at Baird's 2020 Virtual Global Healthcare Conference on Thursday, September 10, 2020 at 8:30 a.m. ET. Jamey Mock, senior vice president and chief financial officer for PerkinElmer, will provide an overview of the Company and its strategic priorities. A live audio webcast o

• PerkinElmer Enhances Hand Sanitizer Analyzer to Detect Methanol in 30 Seconds or Less

  8/17/2020

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that its Hand Sanitizer Analyzer instrument can be used to test for the presence of methanol in alcohol-based hand sanitizer products with pass/fail results delivered in 30 seconds or less. Recent warnings and recal

• PerkinElmer Launches Modular and Scalable explorer™ Workstations for High-throughput COVID-19 Detection

  8/17/2020

  PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a series of explorer™ workstations for SARS-CoV-2 testing capable of preparing and running up to 10,000 COVID-19 tests per day. These modular and scalable workstations enable laboratories to ramp up SARS-CoV-2 tes

• PerkinElmer Board Declares Quarterly Dividend - July 23, 2020

  7/23/2020

  The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock July 23, 2020.

• PerkinElmer Launches Online, Open Access COVID-19 Data Dashboards to Accelerate Antiviral Therapeutics Research

  7/22/2020

  PerkinElmer, Inc. , a global leader committed to innovating for a healthier world, today announced that it has launched two online, free-access PerkinElmer COVID-19 Data Dashboards to help the global scientific community accelerate the discovery of COVID-19 antivirals and vaccines. These dashboards are powered

• PerkinElmer Releases New Dried Blood Spot Based COVID-19 Serology Test

  7/21/2020

  PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP ® /DELFIA ® platform, enabling processing of up to 5,000 samples per day. The finger-prick

• PerkinElmer Introduces AuroFlow® AQ Mycotoxin Platform to Support Testing for Top Six Regulated Mycotoxins in Grain Commodities

  7/20/2020

  PerkinElmer Introduces AuroFlow ® AQ Mycotoxin Platform to Support Testing for Top Six Regulated Mycotoxins in Grain Commodities Features water-based testing strips and handheld reader delivering convenience and accuracy

• PerkinElmer Updates Second Quarter Outlook; To Hold Earnings Call on Tuesday, July 28, 2020

  7/13/2020

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates growth in both reported revenue and organic revenue1 of approximately 12% for the second quarter ended July 5, 2020.

• PerkinElmer and American Society of Hematology Announce Global Collaboration to Help Combat Sickle Cell Disease

  6/18/2020

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced a collaboration with the American Society of Hematology (ASH), the world's largest professional society of hematologists, to support a new effort to increase capacity for newborn screening, education, and cli

• PerkinElmer Launches Pre-eclampsia Kit for Enhanced Management

  6/10/2020

  Addition of sFlt-1 for second and third trimester pre-eclampsia management rounds out portfolio

• PerkinElmer to Present at Jefferies Global Healthcare Conference

  5/20/2020

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the (virtual) Jefferies Global Healthcare Conference on Thursday, June 4, 2020 at 9:00 a.m. ET.

• Official Statement from PerkinElmer in Response to Reuters Article Published on May 18, 2020

  5/18/2020

  PerkinElmer, Inc. (NYSE: PKI) supports government efforts to identify and prevent abusive practices in healthcare. PerkinElmer has received subpoenas from the government regarding investigations into third parties, and has fully cooperated with authorities and will continue to do so.

• PerkinElmer Receives AOAC INTERNATIONAL First Action Official Methods of Analysis (OMA) Status for Solus One Salmonella Assay

  5/11/2020

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced its Solus One™ Salmonella assay and methods have been granted First Action Official Methods of Analysis℠ (OMA) status, number 2020.03, from AOAC INTERNATIONAL (Association of Official Analytical Collaboration).

•  FDA Provides Emergency Use Authorization to PerkinElmer for Serological Test to Identify COVID-19 Antibodies

  5/5/2020

  FDA Provides Emergency Use Authorization to PerkinElmer for Serological Test to Identify COVID-19 Antibodies

• PerkinElmer Announces Financial Results for the First Quarter of 2020

  5/5/2020

  PerkinElmer, Inc., a global leader committed to innovating for a healthier world, reported financial results for the first quarter ended April 5, 2020.

• 

  Biopharma Update on the Novel Coronavirus: May 5

  5/5/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.

• PerkinElmer to Present at BofA Securities Virtual Healthcare Conference 2020

  5/1/2020

  PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual BofA Securities Virtual Healthcare Conference 2020 on Thursday, May 14, 2020 at 8:20 a.m. ET.

• PerkinElmer Board Declares Quarterly Dividend payable on August 7, 2020

  4/30/2020

  The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock on April 30, 2020.

• 

  Biopharma Update on the Novel Coronavirus: April 28

  4/28/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.

• PerkinElmer Launches Solutions to Streamline Analysis for Labs in Pharmaceuticals, Semiconductors, Biomonitoring, Food and Materials

  4/20/2020

  Multi-Quadrupole ICP-MS, FT-IR and automation innovations provide testing and research performance, flexibility and ease of use